Orca Energy Group Inc. Announces Completion of Q2 2025 Interim Filings
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
5 hours ago
- CBC
Chinese tariffs on Canadian canola have farmers bracing for the worst
A new Chinese tariff of over 75 per cent on Canadian canola seed takes effect today, effectively closing Canada's biggest export market for the product. The tariffs are an escalation in a mounting trade dispute between the two countries.
Toronto Star
7 hours ago
- Toronto Star
EnWave to Report Third Quarter Financial Results on August 21, 2025 and Host Investor Conference Call
VANCOUVER, British Columbia, Aug. 14, 2025 (GLOBE NEWSWIRE) — EnWave Corporation (TSX-V:ENW | FSE:E4U) ('EnWave', or the 'Company') announced today it will report its financial results for the third quarter ended June 30, 2025 on Thursday, August 21, 2025 after market close. The financial statements and MD&A will be available on SEDAR at and on the Company's website in the late evening Vancouver time. The Company has scheduled a conference call to discuss the results for Q3 2025 and business outlook on Friday, August 22, 2025 at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time). Brent Charleton, Chief Executive Officer and Dylan Murray, Chief Financial Officer will present EnWave's results and host a question and answer period.
Cision Canada
7 hours ago
- Cision Canada
Light AI reports Financial Results for Three and Six Months ended June 30, 2025
VANCOUVER, BC, /CNW/ - Light AI Inc. (" Light AI" or the " Company") (CBOE: CA) (CBOE: ALGO) (FSE: 0HC) (OTCQB: OHCFF), a healthcare technology company focused on developing artificial intelligence ("AI") health diagnostic and wellness solutions, today announced its financial and operating results for its second quarter of 2025 representing the three and six months ended June 30, 2025. Financial information is reported in Canadian dollars ("$") unless otherwise stated and in accordance with International Financial Reporting Standards ("IFRS"). Financial and Operating Results Summary for the three and six months ended June 30, 2025 The Company is currently in the development stage of its software technology offering anticipated to be completed with related commercialization commencing in late 2025. During the three months ended June 30, 2025, the Company had total operating expenses, exclusive of interest, depreciation and share based payments, of $4.0 million compared to $4.2 million for the three months ended March 31, 2025 and $2.0 million for the three months ended June 30, 2025. The change is primarily attributable to the Company's incremental investment in its product development with total research and development expenses of $1.4 million in Q2 2025 compared to $1.2 million for the three months ended March 31, 2025 and $1.1 million in the prior year period in addition to marketing and investor relations activities of approximately $2.1 million in Q2 2025 compared to $2.4 million for the three months ended March 31, 2025 and $0.3 million in the prior year period. The Company had total operating expenses of $8.3 million for the six months ended June 30, 2025 which increased from $3.8 million in the prior year period due primarily to marketing and investor relations expenses in addition to increased product development costs. The Company had cash of $9.4 million with total assets of $10.8 million as at June 30, 2025 compared to cash of $15.2 million with total assets of $17.1 million as at December 31, 2024. On January 8, 2025, the Company closed the second of two tranches of the Offering by issuing 2,757,000 units of the Company at $0.55 per unit for aggregate gross proceeds of $1,516,350. The Company had Adjusted Working Capital of $8.9 million as at June 30, 2025 compared to $14.6 million as at December 31, 2024. "Light AI continues to make progress towards commercializing its AI oriented wellness software application anticipated to be commercially available after Q3 2025," stated Peter Whitehead, CEO. "We are well positioned to capitalize on our sizable market opportunity leveraging Light AI's first mover advantage with our patented intellectual property and technology." Financial Statements and Management Discussion & Analysis Please see the Company's consolidated financial statements ("Financial Statements") and related Management's Discussion & Analysis ("MD&A") for more details. The Financial Statements for the three and six months ended June 30, 2025, and related MD&A have been reviewed and approved by the Company's Audit Committee and Board of Directors. For a more detailed explanation and analysis, please refer to the MD&A that has been filed on SEDAR+ at and is also available on the Company's website at Non-IFRS and Other Financial Measures This press release refers to the following non-IFRS measures: "Adjusted Working Capital" is comprised as current assets less current liabilities. Management believes Adjusted Working Capital is a useful indicator for investors, and is used by management, for evaluating the operating liquidity to the Company. See "Adjusted Working Capital Reconciliation" for a quantitative reconciliation of Adjusted Working Capital to the most directly comparable financial measure. Such non-IFRS measures and non-IFRS ratio do not have a standardized meaning under IFRS and may not be comparable to a similar measure disclosed by other issuers. About Light AI Inc. (CBOE CA: ALGO / FSE: 0HC / OTCQB: OHCFF) Light AI Inc. is a technology company focused on developing artificial intelligence health screening and diagnostic solutions. Light AI is developing a technology platform which represents the next generation of patient management: it applies AI algorithms to smartphone images—starting with images of Strep A and anticipated expansion with COVID19 along with other medical conditions —to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind—its hardware platform is the 4.5 billion smartphones that exist in the world today. Light AI is at the forefront of developing innovative screening and diagnostic solutions aimed at improving healthcare delivery worldwide. Their cutting-edge AI powered technology offers rapid, accurate, and cost-effective screening and diagnostic tools designed to address critical healthcare challenges. In pre-FDA validation studies, Light AI's algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A Streptococcus (GAS). The algorithm achieved a 96.57% accuracy rate and attained a Negative Predictive Value of 100%, indicating its high reliability in confirming the absence of Streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as Rheumatic Heart Disease (RHD), which imposes a global economic burden exceeding $1 trillion annually. Light AI's technology offers a significant advancement in the accurate and timely identification of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs. Light AI's approach to applying AI to smartphone images can be expanded to other throat conditions, as well as other areas of analysis, such as the human eye and skin. Light AI's vision is to combine the smartphone with AI in-the-Cloud to create a Digital Clinical Lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time-consuming imaging or lab processes. Light AI's commercial launch of its consumer-facing Wellness App initial offering is anticipated to be available in North America in Q3 2025. ON BEHALF OF THE COMPANY "George Reznik" George Reznik Chief Financial Officer Telephone: 604-307-6800 Email: [email protected] For more information, please contact the Company at [email protected] or visit Forward-Looking Information: This news release includes information, statements, beliefs and opinions which are forward-looking, and which reflect current estimates, expectations and projections about future events, including, but not limited to, the Company's research and development and commercialization initiatives, the anticipated inflection of the business, the Company's financial and operational performance and outlook and other statements that contain words such as "believe," "expect," "project," "should," "seek," "anticipate," "will," "intend," "positioned," "risk," "plan," "may," "estimate" or, in each case, their negative and words of similar meaning. By its nature, forward-looking information involves a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking information. These risks, uncertainties and assumptions could adversely affect the outcome of the plans and events described herein. Readers should not place undue reliance on forward-looking information, which is based on the information available as of the date of this news release. For a list of the factors that may affect any of the Company's forward-looking statements, please refer to the Company's annual information form dated April 14, 2025 and other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed under its SEDAR+ profile at
